Navigation Links
Study Shows Improved Patient Management and Outcome Using Abbott's Sensitive Troponin Assay
Date:5/18/2011

BERLIN, May 18, 2011 /PRNewswire/ -- Research presented this week at the International Federation of Clinical Chemistry Congress and Laboratory Medicine showed that using a lower diagnostic threshold for troponin improves clinical outcomes and patient survival in patients with suspected acute coronary syndromes.  Troponin is a protein found inside of heart cells that is released when they are damaged by ischemia or reduced blood supply.  

Cardiac troponin is regarded by clinicians as one of the most specific biochemical markers for myocardial tissue injury, and the latest generation of more sensitive assays can identify patients with very small heart attacks.  By improving the ability to accurately triage patients presenting with chest pain, the use of sensitive troponin assays could provide physicians with important information to help reduce patient deaths.  

The diagnostic threshold used during the validation phase was 0.20 ng/mL.  During the implementation phase, the diagnostic threshold was lowered to 0.05 ng/mL.  The 2,092 patients with suspected ACS who presented at the Royal Infirmary of Edinburgh were stratified in three groups (troponin <0.05 ng/mL, 0.05 to 0.19 ng/mL, and greater than or equal to 0.20 ng/mL).  

During the validation phase, 39 percent of patients with troponin concentrations of 0.05 to 0.19 ng/mL died or were readmitted with MI at one year.  In contrast, only 21 percent of patients with troponin concentrations of 0.05 to 0.19 died or had a recurrent MI during the implementation phase.  Lowering the diagnostic threshold resulted in more referrals to specialists and better treatment, explaining the improvement in clinical outcomes in these patients.

Nicolas Mills, M.D., Ph.D., a cardiologist at the British Heart Foundation Centre for Cardiovascular Science, and Simon Walker, M.D., Ph.D., a senior lecturer and consultant in the Department of Clinical Biochemistry a
'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Positive Results from Long-Term Phase 3 Study of Avanafil Featured at American Urological Association Annual Meeting
2. Food Allergies Common among Children and Linked to Environmental Allergies and Asthma Later in Life, Suggests Largest-Ever National Allergy Study
3. Exploratory Efficacy Analysis Conducted for Long-Term Extension Study in Patients With Prostate Cancer Treated With FIRMAGON® or Crossed Over to FIRMAGON From Leuprolide
4. Caldolor® Clinical Study in Hospitalized Burn Patients Published in Journal of Burn Care & Research
5. Initiation of Antiretroviral Treatment Protects Uninfected Sexual Partners from HIV Infection (HPTN Study 052)
6. CrystalGenomics Completes Phase I MAD Study of its Novel Antibiotic Candidate CG400549, and Prepares for Phase II Clinical Study
7. Kaiser Permanente Study Challenges Concerns on Effectiveness of Administering Pneumococcal & Shingles Vaccines Together
8. Star Scientific Files First Quarter Report, Updates Details of Flint Study Using RCP-006
9. Independent Investigator Initiates Phase 1 Study of Biodels Ultra-Rapid-Acting Insulin Formulations in Patients Using Insulin Pumps
10. Selexys Pharmaceuticals Initiates Enrollment in Phase I Clinical Study of SelG1
11. SAR 1118 Demonstrates Encouraging Results in Phase 2 Study of Dry Eye Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... FREDERICK, Md. , May 21, 2013 /PRNewswire/ ... inexpensive, disposable drug-free consumer electronic devices, announced that ... is presenting today to the FDA,s Medical Advisory ... reclassifying the company,s products for over the counter ... the FDA developed its medical device classification schema," ...
(Date:5/21/2013)... , May 21, 2013  Janssen R&D Ireland ... from the global Phase 3 PROMISE study demonstrating ... (TMC435) led to sustained virologic response 12 weeks ... percent of treatment-experienced genotype 1 chronic hepatitis C ... stages of liver fibrosis, when administered once daily ...
(Date:5/21/2013)... , May 21, 2013 ... report is available in its catalogue: ... and Reimbursement Scenario for Medical Devices in ...   Changing Regulatory ... the US Market   ...
Breaking Medicine Technology:BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4
... M. Bergman, Chairman and Chief Executive Officer of ... the largest provider of health care products and ... impact of a world without effective antibiotics before ... leaders of society at the World Economic Forum,s ...
... 2012  Vision-Sciences, Inc. (NASDAQ:  VSCI), a leading provider ... disposable EndoSheath® technology, today announced its participation at ... TIME: 2:30 PM EST ... "register/ watch event now" button. This ...
Cached Medicine Technology:Henry Schein's Chairman and CEO Addresses the World Economic Forum 2Henry Schein's Chairman and CEO Addresses the World Economic Forum 3Vision-Sciences, Inc. to Webcast, Live, at RetailInvestorConferences.com on February 2nd 2
(Date:5/21/2013)... have long been known for their health benefits, ... therapies like anti-cancer drugs are delivered to specific ... uncovered how to create nanoparticles using natural lipids ... use them as drug delivery vehicles. UofL scientists ... their team today (May 21, 2013), published their ...
(Date:5/21/2013)... Residents in St. Petersburg, FL have a ... Dr. David Sherberg, DMD, has joined Coast Dental Pasadena, ... provides preventive, restorative and cosmetic dentistry to patients age ... provide a wide variety of services including ... crowns, bridges, dentures, dental implant restorations, veneers, laser therapy, ...
(Date:5/21/2013)... May 21, 2013 Vyopta Incorporated, ... automation applications for video collaboration, today announced the ... index evaluates key performance metrics related to quality, ... immediate, aggregated indicator of the performance of their ... Vyopta vAnalytics™ application, the vRating™ delivers high level ...
(Date:5/21/2013)... TheBeautyPlace.com helps brides to breathe a ... Big Day Kit including all the essentials a glowing ... on their Wedding Day. , TheBeautyPlace.com features Wedding Day ... their Wedding Day. Flowers blooming and warmer weather indicates ... season. From Memorial Day to October, brides to be ...
(Date:5/21/2013)... the sound of galloping hooves behind you, your immediate reaction ... it is actually a zebra approaching. Doctors are trained to ... their practices, and as they rarely or never meet a ... takes many years to reach the right diagnosis. A new ... many cases. , Ole Winther is Associate Professor at ...
Breaking Medicine News(10 mins):Health News:UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery 2Health News:Coast Dental Pasadena Welcomes Dr. David Sherberg 2Health News:Coast Dental Pasadena Welcomes Dr. David Sherberg 3Health News:New vRating™ Video and Unified Communications Scoring System Delivers Innovative Approach to Measure Performance and ROI for Collaboration Networks 2Health News:New vRating™ Video and Unified Communications Scoring System Delivers Innovative Approach to Measure Performance and ROI for Collaboration Networks 3Health News:TheBeautyPlace.com Previews their Emergency Big Day Kit to Get Brides Ready For this Upcoming Wedding Season 2Health News:TheBeautyPlace.com Previews their Emergency Big Day Kit to Get Brides Ready For this Upcoming Wedding Season 3Health News:New search engine finds rare diagnoses 2Health News:New search engine finds rare diagnoses 3
... May 16 /Xinhua-PRNewswire-FirstCall/ -- BMP,Sunstone Corporation (Nasdaq: BJGP ) ... that the Company,will present at the following conferences:, ... cities in China. David Gao, ... scheduled to present on May 19, 2008, ...
... University of Texas M. D. Anderson Cancer Center have ... shutting down their energy source and hastening cell starvation. ... fellow from the Children,s Cancer Hospital at M. D. ... with mTOR inhibitor, rapamycin, induced more than 90 percent ...
... Available, RADNOR, Pa., May 16 This ... Older Pennsylvanians Month, Feeling Blue,Suicide Prevention Council (SPC) ... a public service announcement. The public service,announcement developed ... awareness,to the public health problem of depression and ...
... Conn., May 16 Tao Formulations announces ... Relief Formula, at the Internal,Medicine 2008 conference ... culmination of years of research to develop ... menopausal symptoms., Company founder and CEO, ...
... 2 Diabetes and High LDL- ... Cholesterol ... ACE/AACE Road Maps, PARSIPPANY, N.J., May 16 Daiichi Sankyo, Inc. (DSI),announced ... combination with metformin- or,sulfonylurea- based therapy, significantly lowers blood glucose (as,measured by A1C) ...
... number of women undergoing mastectomy (total breast removal) for ... years at Mayo Clinic in Rochester. The increase follows ... Researchers say the reasons for this increase are unclear. ... who underwent diagnostic magnetic resonance imaging (MRI) prior to ...
Cached Medicine News:Health News:BMP Sunstone Announces Participation in May Investor Conferences 2Health News:New drug combination brings 1-2 punch against acute leukemia 2Health News:Suicide Prevention Group Delivers Much-Needed Message to Pennsylvania's Elderly 2Health News:Tao Formulations Announces the Official Launch of Tao Harmony - Menopause Relief Formula 2Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 2Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 3Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 4Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 5Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 6Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 7Health News: Mastectomies on the rise and MRI use may explain part of the trend, say Mayo researchers 2Health News: Mastectomies on the rise and MRI use may explain part of the trend, say Mayo researchers 3
Designed to insert eye spheres using spring loaded plunger. Polished finish. Overall length: 125 mm, 4.9 inches....
Size: Large. 24.50 mm by 26.00 mm. Clear lucite. Supplied sterile....
... x 80 mm. Storz offers the ... by Harvey A. Lincoff, M.D. ... sponge which is non-toxic and non-antigenic. ... to minimize scleral intrusion. These implants ...
... 5.0 x 80 mm. Storz offers ... designed by Harvey A. Lincoff, M.D. ... sponge which is non-toxic and non-antigenic. ... to minimize scleral intrusion. These implants ...
Medicine Products: